Idecabtagene Vicleucel

Patients with hematologic malignancies reported significant improvement in quality of life after receiving chimeric antigen receptor T cells, results from a longitudinal study in Blood Advances showed.

Adults with advanced multiple myeloma and renal insufficiency treated with idecabtagene vicleucel achieved similar outcomes as those with normal renal function, according to retrospective study results.

Only a decade ago, many in oncology considered chimeric antigen receptor T-cell therapy too fringe for real-world use.

Idecabtagene vicleucel significantly extended PFS compared with standard regimens for adults with triple-class refractory multiple myeloma, results of the randomized phase 3 KarMMa-3 trial showed.

NEW ORLEANS — In this video perspective, Samer Al Hadidi, MD, MS, FACP, discusses research evaluating G protein–coupled receptor as a new target for therapy in relapsed refractory multiple myeloma.

NEW ORLEANS — Idecabtagene vicleucel induced initial complete remission in nearly half of patients with multiple myeloma who had early relapse after front-line therapy, results of a cohort analysis of the phase 2 KarMMa-2 trial showed.

The FDA approval of the first ever chimeric antigen receptor T-cell therapy for multiple myeloma in 2021 laid the groundwork for others to follow.

Idecabtagene vicleucel extended PFS compared with standard regimens for adults with advanced multiple myeloma, according to topline data released by the agent’s manufacturer.

Although chimeric antigen receptor T-cell therapy is approved for treatment of multiple myeloma, commercially available products are limited to patients who received at least four prior lines of therapy.

Chimeric antigen receptor T-cell therapy has induced exceptional response rates among patients with relapsed or refractory multiple myeloma compared with conventional options, according to a speaker at Chemotherapy Foundation Symposium.